Pfizer: FDA gives Xtandi priority review
(CercleFinance.com) - Pfizer announced on Thursday that the US drug regulator, the FDA, has granted priority review to Xtandi, a prostate cancer treatment that the US laboratory is developing in collaboration with the Japanese group Astellas.
The Food and Drug Administration's decision concerns the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC)
The drug is already approved in the United States for the treatment of castration-resistant prostate cancer (CRPC).
A target date for the release of the final FDA notice has been set in Q4 this year.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The Food and Drug Administration's decision concerns the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC)
The drug is already approved in the United States for the treatment of castration-resistant prostate cancer (CRPC).
A target date for the release of the final FDA notice has been set in Q4 this year.
Copyright (c) 2019 CercleFinance.com. All rights reserved.